GTBP - GT Biopharma GAAP EPS of -$0.22 misses by $0.11
- GT Biopharma press release ( NASDAQ: GTBP ): Q3 GAAP EPS of -$0.22 misses by $0.11 .
- $20.8 million in cash, cash equivalents and short-term investments as of September 30, 2022, is expected to provide runway to fund operations into 2023.
For further details see:
GT Biopharma GAAP EPS of -$0.22 misses by $0.11